Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into ...

The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the ...

The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time ...

Medicare selects Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower ...

The 15 drugs selected for negotiation include Eli Lilly’s breast-cancer drug Verzenio.

The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...

Medicare said it will negotiate prices for its 15 highest spending drugs, mainly for cancer, autoimmune disorders, and chronic conditions.

The Trump administration on Tuesday announced the next round of prescription drugs up for Medicare price negotiations.

CMS names medications 2028 for Medicare price negotiation, including Trulicity and Biktarvy, targeting high-cost drugs in ...

President Donald Trump and the Centers for Medicare & Medicaid Services (CMS) recently announced the 15 drugs whose prices ...

List includes medications for diabetes, cancer, arthritis, and more ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...